Aequus Completes ZIMED PF Sale and Moves Listing to NEX Board

An announcement from Aequus Pharmaceuticals ( (TSE:AQS) ) is now available.

Aequus Pharmaceuticals has completed the sale of its ZIMED PF product to Luvo Medical Technologies for total consideration of about $531,693, following shareholder approval of the divestiture as a sale of all or substantially all of the company’s assets. The deal was revised to replace a planned 6% ongoing royalty with a one-time lump-sum royalty payment of roughly $131,693, eliminating future royalty obligations and cancelling a proposed royalty assignment to Aequus’ CEO while also triggering a transfer of the company’s listing to the NEX board of the TSX Venture Exchange, signaling a significant strategic shift in its operations and market positioning.

The most recent analyst rating on (TSE:AQS) stock is a Sell with a C$0.01 price target. To see the full list of analyst forecasts on Aequus Pharmaceuticals stock, see the TSE:AQS Stock Forecast page.

Spark’s Take on AQS Stock

According to Spark, TipRanks’ AI Analyst, AQS is a Underperform.

The score is driven primarily by weak financial fundamentals: ongoing large losses, continued cash burn, and a highly strained balance sheet with negative equity and debt exceeding assets. Technical signals provide limited support and valuation is constrained by a negative P/E and lack of dividend data.

To see Spark’s full report on AQS stock, click here.

More about Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. is a Canadian specialty pharmaceutical company focused on commercializing value-added products in specialty therapeutic areas in the domestic market. The company operates on the TSX Venture Exchange and targets niche segments where it can differentiate products and build commercial relationships with healthcare providers.

Average Trading Volume: 10,000

Technical Sentiment Signal: Sell

Current Market Cap: C$663.2K

Find detailed analytics on AQS stock on TipRanks’ Stock Analysis page.